article = {GSCR-2021-1-103}
title = {Salvage Lymphadenectomy as a Treatment of Prostate Cancer Recurrence}
journal = {Global Surgery Case Reports}
year = {2021}
issn = {2733-2535}
doi = {http://dx.doi.org/10.31487/j.GSCR.2021.01.03}
url = {https://www.sciencerepository.org/salvage-lymphadenectomy-as-a-treatment-of-prostate-cancer-recurrence_GSCR-2021-1-103 
author = {Donghua  Xie,Yanda  LU,Di  Gu,Ming Lei,Cong  Cai,Wen  Zhong,Defeng  Qi,Wenqi  Wu,Yongda  Liu,Guohua  Zeng,}
keywords = {Salvage lymphadenectomy, prostate cancer, radical prostatectomy, positron emission tomography, biochemical recurrence, biochemical response}
abstract ={Biochemical recurrence (BCR) occurs up to 40% of men who had radical prostatectomy for localized prostate cancer. Regional nodes are usually involved in these cases. Salvage lymphadenectomy (sLND) has been advocated in patients with 'node-only' metastasis with biochemical recurrence, following a definitive treatment of primary prostate cancer. In general, limited case number was reported for each previous study. Four relatively larger reports so far with the highest case number of 189. One randomized controlled study has been completed so far at Phase II level. Salvage LND seems to be safe with relatively low incidence of complications without perioperative mortality. It may postpone adjuvant therapy in selected cases, avoiding systemic side effects and possibly reducing the cost. However, long-term outcome is not very encouraging.}